Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

5mg/kg intravenous infusion on Day 1 of each cycle (every 21 days). Duration: 3 or 6 cycles

"Bevacizumab: 7.5mg/kg intravenous infusion on Day 1 of each cycle (every 21 days).~Capecitabine: 1000 mg/m2 twice daily orally on Day 1-14 of each cycle (every 21 days).~Oxaliplatin: 130 mg/m2 intravenous infusion on Day 1 of each cycle (every 21 days).~Duration:~Conversion therapy phase: 3 or 6 cycles; Postoperative follow-up phase (for patients with successful conversion surgery ): 3 or 6 cycles (a total perioperative duration of 9 cycles); Maintenance phase (for patients without successful conversion surgery ): Continuous therapy until disease progression, intolerable adverse events, withdrawal of consent, loss to follow-up, death, or study termination."

After 3 or 6 cycles of conversion therapy, surgical resection ± ablation or stereotactic radiotherapy will be provided if applicable.